1. Home
  2. VRAX vs XBIO Comparison

VRAX vs XBIO Comparison

Compare VRAX & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virax Biolabs Group Limited

VRAX

Virax Biolabs Group Limited

HOLD

Current Price

$0.36

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Logo Xenetic Biosciences Inc.

XBIO

Xenetic Biosciences Inc.

HOLD

Current Price

$2.16

Market Cap

5.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRAX
XBIO
Founded
2013
N/A
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9M
5.9M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
VRAX
XBIO
Price
$0.36
$2.16
Analyst Decision
Strong Buy
Hold
Analyst Count
1
1
Target Price
$3.00
N/A
AVG Volume (30 Days)
15.5M
35.4K
Earning Date
01-01-0001
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,986.00
$2,858,935.00
Revenue This Year
$217,274.83
$1.99
Revenue Next Year
N/A
$20.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
13.30
52 Week Low
$0.31
$1.90
52 Week High
$3.20
$13.93

Technical Indicators

Market Signals
Indicator
VRAX
XBIO
Relative Strength Index (RSI) 40.69 41.11
Support Level $0.31 $1.95
Resistance Level $0.43 $2.29
Average True Range (ATR) 0.04 0.14
MACD -0.01 0.02
Stochastic Oscillator 25.29 41.27

Price Performance

Historical Comparison
VRAX
XBIO

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).

About XBIO Xenetic Biosciences Inc.

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.

Share on Social Networks: